Table 3. Univariable analysis of PFS and PFS-P.
| Variable | PFS-P | PFS | |||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
| Gender (female vs. male) | 0.647 (0.080–5.213) | 0.68 | 0.038 (0.000–161.997) | 0.44 | |
| Age (<65 vs. ≥65 years) | 3.334 (0.740–15.013) | 0.12 | 4.979 (1.084–22.877) | 0.04 | |
| Smoking status (no vs. yes) | 0.806 (0.234–2.782) | 0.73 | 0.483 (0.119–1.958) | 0.31 | |
| ECOG PS (0–1 vs. 2) | 0.078 (0.074–15.013) | 0.04 | 0.170 (0.028–1.031) | 0.054 | |
| Brain metastasis (no vs. yes) | 0.635 (0.183–2.200) | 0.47 | 0.284 (0.063–1.284) | 0.10 | |
| Liver metastasis (no vs. yes) | 0.143 (0.013–1.575) | 0.11 | 0.071 (0.004–1.142) | 0.06 | |
| Bone metastasis (no vs. yes) | 0.574 (0.173–1.910) | 0.37 | 0.613 (0.176–2.132) | 0.44 | |
| Lung metastasis (no vs. yes) | 0.857 (0.184–3.985) | 0.11 | 1.348 (0.260–6.977) | 0.72 | |
| Previous immunotherapy (no vs. yes) | 1.397 (0.366–5.328) | 0.63 | 2.156 (0.538–8.634) | 0.28 | |
| LIPI (0 vs. ≥1) | 0.555 (0.114–2.692) | 0.46 | 0.460 (0.092–2.299) | 0.34 | |
PFS, progression-free survival; PFS-P, progression-free survival post-oligoprogression; CI, confidence interval; ECOG PS, performance score of Eastern Cooperative Oncology Group; LIPI, lung immune prognostic index.